Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 26, 2021; 9(6): 1359-1366
Published online Feb 26, 2021. doi: 10.12998/wjcc.v9.i6.1359
Published online Feb 26, 2021. doi: 10.12998/wjcc.v9.i6.1359
Noninvasive tools based on immune biomarkers for the diagnosis of central nervous system graft-vs-host disease: Two case reports and a review of the literature
Hai-Rong Lyu, Xiao-Yuan He, Wen-Yi Lu, Ming-Feng Zhao, Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin 300192, China
Hong-Jun Hao, Department of Neurology, Peking University First Hospital, Beijing 100034, China
Xin Jin, School of Medicine, Nankai University, Tianjin 300071, China
Yu-Jiao Zhao, Department of Radiology, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin 300192, China
Author contributions: Lyu HR and Zhao MF contributed equally to this work; Lyu HR and He XY wrote the manuscript; Lyu HR, He XY, Hao HJ and Zhao YJ performed the experiments and analyzed the data; Lu WY and Jin X followed up on the patients; all authors have read and approved the final manuscript.
Supported by National Natural Sciences Foundation of China , No. 81970180 and 81800105 ; Natural Science Foundation of Tianjin Municipal Science and Technology Commission , China, No. 17JCZDJC35800; and Tianjin Health and Family Planning Commission , China, No. 16KG110.
Informed consent statement: All study participants, or their legal guardian, provided written informed consent prior to study enrollment.
Conflict-of-interest statement: All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Feng Zhao, DPhil, PhD, Chief Doctor, Chief Physician, Department of Hematology, Tianjin First Central Hospital, School of Medicine, Nankai University, No. 24 Fukang Road, Nankai District, Tianjin 300192, China.
Received: September 12, 2020
Peer-review started: September 12, 2020
First decision: November 29, 2020
Revised: December 9, 2020
Accepted: December 16, 2020
Article in press: December 16, 2020
Published online: February 26, 2021
Processing time: 140 Days and 20.8 Hours
Peer-review started: September 12, 2020
First decision: November 29, 2020
Revised: December 9, 2020
Accepted: December 16, 2020
Article in press: December 16, 2020
Published online: February 26, 2021
Processing time: 140 Days and 20.8 Hours
Core Tip
Core Tip: We systematically report the diagnostic methods used for central nervous system graft-vs-host disease and present our own diagnostic criteria. Furthermore, we propose that non-invasive tools, especially cerebrospinal fluid and blood immune biomarker examinations, facilitated the diagnosis of central nervous system graft-vs-host disease, which are particularly suitable for patients who are critically ill and require urgent treatment and for those who are unsuitable for invasive diagnostic procedures.